Closing a peptide into a ring buys three things at once: conformational rigidity<\/strong> (pre-organized to hit its target, paying less entropic penalty on binding), proteolytic stability<\/strong> (no free termini for exopeptidases; often unnatural residues that endopeptidases don’t recognize), and \u2014 the prize the field is chasing \u2014 the possibility of oral bioavailability<\/strong>. The review’s central data-driven message is that oral administration is gaining attention, signaling real progress against the class’s long-standing bioavailability problem.<\/p>\n\n\n\n There is one catch that shapes everything below. Cyclic peptides typically occupy an intermediate molecular-weight range of\u00a0\u223c500\u20133000 Da<\/strong>, sitting between small molecules and large biologics. So a\u00a0molecular-weight ceiling of 900 Da is a genuinely restrictive filter<\/strong>\u00a0\u2014 it selects the small, most “drug-like” tail of the class, where oral absorption is most plausible. Most of the clinical pipeline sits well above it. <\/p>\n\n\n\n Four represent the two great “success stories” of small cyclic peptides \u2014 HCV protease inhibitors and natural-product-derived HDAC\/integrin ligands \u2014 and one is a current oncology frontrunner.<\/p>\n\n\n\n Together they span oncology, antivirals, and hematologic malignancy<\/strong>, and three distinct ring-forming chemistries \u2014 head-to-tail amide macrolactamization (cilengitide), disulfide\/depsipeptide (romidepsin), and olefin metathesis (grazoprevir, voxilaprevir).<\/p>\n\n\n\n Cilengitide is the ideal teaching synthesis because it showcases, in one molecule, the three design tricks that define modern cyclic-peptide medicinal chemistry: a D-amino acid<\/strong> (D-Phe), an N-methylated residue<\/strong> (N-methyl-Val), and head-to-tail cyclization<\/strong> \u2014 all layered on the biologically critical RGD<\/strong> recognition motif.<\/p>\n\n\n\n The strategy, step by step:<\/strong><\/p>\n\n\n\n This SPPS-then-cyclize logic \u2014 build linear on resin, cleave with protection intact, close the ring in dilute solution, then deprotect \u2014 is the workhorse route to most head-to-tail cyclic peptides, and it maps directly onto the review’s discussion of cyclization strategy and chemical modification.<\/p>\n\n\n\n Cyclic peptides remain medicinal chemistry’s “middle kingdom” \u2014 and as the oral-delivery problem yields, that middle ground is exactly where a lot of the next decade’s drugs will be found.<\/p>\n\n\n\n A tour through the cyclic-peptide landscape mapped by Thite et al. (J. Med. Chem. 2026, 69, 17770\u201317799) \u2014 with five clinical-stage compounds under 900 Da, their chemistry and targets, and a worked solid-phase synthesis of the one that taught the field its hardest lesson.<\/em> Why cyclic peptides matter Drug discovery has long been split between two worlds: small molecules (cheap, oral, cell-permeable, but often unable to grip large flat protein surfaces) and biologics (exquisitely specific, but injectable, expensive, and locked out of the cell). Cyclic peptides…<\/p>\n","protected":false},"author":1,"featured_media":121,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-118","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"_links":{"self":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/118","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/comments?post=118"}],"version-history":[{"count":1,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/118\/revisions"}],"predecessor-version":[{"id":122,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/118\/revisions\/122"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/media\/121"}],"wp:attachment":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/media?parent=118"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/categories?post=118"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/tags?post=118"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"\"](\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/08\/image-6-1024x776.png\")
<\/figure>\n\n\n\n\n
cyclo(-Arg-Gly-Asp-D-Phe-N(Me)Val-)<\/code>, a selective\u00a0\u03b1v\u03b23\/\u03b1v\u03b25 integrin<\/strong>\u00a0antagonist. It reached\u00a0Phase III in glioblastoma<\/strong>\u00a0and, though it ultimately failed to extend survival, it remains the single most instructive molecule in the field for teaching cyclic-peptide design (see the synthesis below).<\/li>\n\n\n\nA worked synthesis: cilengitide by Fmoc SPPS + macrolactamization<\/h2>\n\n\n\n
![\"\"](\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/08\/image-7-1024x623.png\")
<\/figure>\n\n\n\n\n
The bigger medicinal-chemistry lessons<\/h2>\n\n\n\n
\n
<\/p>\n","protected":false},"excerpt":{"rendered":"